Investment case
ABVC BioPharma, Inc.
ABVC · 2 developments mapped · last assessed 2026-08-27
Market Ontology has mapped 2 macro, policy, and market developments to ABVC BioPharma, Inc. since 2026-08-27. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for ABVC yet, so no modelled value is shown. The ABVC valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run ABVC on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Open question
ABVC BioPharma Announces Spin-Off of BioKey (Cayman), Inc.
Direct corporate restructuring, asset divestiture, and potential re-rating of remaining business.
· Moves future growth rates of remaining business, cost of capital (wacc) due to potential change in risk profile, terminal multiple reflecting focused operations
What changed, by assumption
- 2026-08-27ABVC BioPharma Announces Spin-Off of BioKey (Cayman), Inc.
- 2026-08-27ABVC BioPharma Completes Spin-off of BioKey (Cayman), Inc.
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-08-12 | Revenue | Bearish | Spun-off business revenue exits parent consolidated P&L. | 0.70 |
| 2026-08-12 | Valuation multiple | Bullish | Spin-off removes conglomerate discount on remaining parent. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-08-27 | ABVC BioPharma Announces Spin-Off of BioKey (Cayman), Inc. | mixed | 3-12m | 0.70 |
| 2026-08-27 | ABVC BioPharma Completes Spin-off of BioKey (Cayman), Inc. | mixed | 1-3m | 0.70 |